Bicara Therapeutics Inc. (BCAX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor... Read more
Sell if holding. Engine safety override at $20.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Bicara Therapeutics Inc.
Latest news
- NEWS Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Response — benzinga May 21, 2026 positive
- NEWS Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18 — benzinga May 12, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37 — benzinga May 12, 2026 positive
- NEWS Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42 — benzinga May 11, 2026 positive
- NEWS Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate — benzinga May 11, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.56: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $19.12. Score 5.1/10, moderate confidence.
Take-profit target: $27.37 (+33.1% upside). Prior stop was $19.12. Stop-loss: $19.12.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -2.5%), Material insider selling (4 sells, 0.12% of cap).
Bicara Therapeutics Inc. trades at a P/E of N/A (forward -5.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover BCAX with a consensus score of 4.1/5. Average price target: $31.
What does Bicara Therapeutics Inc. do?Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional...
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.